Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	4 Months Ended	5 Months Ended	9 Months Ended
	Sep. 30, 2023	May 17, 2023	Sep. 30, 2024
Operating Activities
Net Income (Loss)	$ (45)	$ 465	$ 945
Non-cash reconciliation adjustments:
Unrealized (gains) losses on derivative instruments	49	65	(59)
(Gain) loss on Cumulus Data Campus Sale and ERCOT Sale	0	0	(886)
(Gain) loss on sales of assets, net	0	(50)	0
Nuclear fuel amortization	72	33	93
Nuclear fuel amortization	71
Depreciation, amortization and accretion	89	208	216
Impairments	2	381	0
NDT funds (gain) loss, net (excluding interest and fees)	1	(43)	(135)
Deferred income taxes	(4)	195	39
Reorganization (income) expense, net	0	(933)	0
Other	23	7	(58)
Changes in assets and liabilities:
Accounts receivable, net	(23)	261	41
Inventory, net	9	10	73
Other assets	45	98	28
Accounts payable and accrued liabilities	(89)	(69)	(115)
Accrued interest	65	(124)	22
Other liabilities	(13)	(42)	42
Net cash provided by (used in) operating activities	180	462	246
Investing Activities
Property, plant and equipment expenditures	(60)	(138)	(58)
Nuclear fuel expenditures	(43)	(49)	(89)
NDT funds investment sale proceeds	768	949	1,646
NDT funds investment purchases	(780)	(959)	(1,670)
Equity investments in affiliates	(3)	(8)	(6)
Proceeds from Cumulus Data Campus Sale and ERCOT Sale (Note 17)	0	0	1,398
Proceeds from the sale of assets	0	46	1
Other investing activities	10	2	3
Net cash provided by (used in) investing activities	(108)	(157)	1,225
Financing Activities
Contributions from member	0	1,393	0
Financing proceeds at Emergence, net of discount	0	2,219	0
Repayment of Prepetition Secured Indebtedness	0	(3,898)	0
Payment of make-whole premiums on Prepetition Secured Indebtedness	0	(152)	0
TLB proceeds, net	289	0	0
LMBE-MC TLB payments	(294)	(7)	0
Cumulus Digital TLF repayment	0	0	(182)
Share repurchases (Note 15)	0	0	(956)
Repurchase of noncontrolling interest	(19)	0	(39)
Cash settlement of restricted stock units	0	0	(31)
Deferred finance costs	(4)	(74)	0
Repurchase of warrants	(40)	0	0
Derivatives with financing elements	0	(20)	0
Other	6	0	(32)
Net cash provided by (used in) financing activities	(62)	(539)	(1,240)
Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash and Cash Equivalents	10	(234)	231
Beginning of period cash and cash equivalents and restricted cash and cash equivalents	754	988	901
End of period cash and cash equivalents and restricted cash and cash equivalents	$ 764	$ 754	$ 1,132